


Figure 1. Polymorph Form C




Figure 2. Polymorph Form B




Figure 3. Amorphous Phase A




Figure 4. XRPD of solids from various Solvents



Amorphous
Phase A at 40°C
and 75%RH
Amorphous Phase A
2-Theta - Scale

Figure 5.




Figure 6.




Figure 7.




Figure 8.




Figure 9.




Figure 10.




Figure 11.




Figure 12. TGA (top) and DSC (bottom) for Amorphous Phase A




Figure 13.




Figure 14. TGA (top) and DSC (bottom) for Polymorph Form B




Figure 15. TGA (top) and DSC (bottom) for Polymorph Form C

Amorphous Phase A




Figure 16.

Form B




Figure 17.

Form C




Figure 18.




Figure 19.



Induction of CYPs
Fold Induction Verses Control
1250
1000
750
500
250
0
CYP3A4
CYP2C9
Vehicle
Rifampicin
Compound 1

Figure 20.



Plasma Concentrations of Compound Following Single Dose Administration
Plasma Conc (log ng/mL)
100000
10000
1000
100
10
0
4
8
12
16
20
24
Time (hr)
50 mg (n = 6)
150 mg (n = 6)
300 mgs (n = 6)
600 mgs (n = 6)
1000 mgs (n = 6)

Figure 21.



% Change in Leukotriene B4 Levels
(Single Dose Cohorts)
% Baseline
300
250
200
150
100
50
0
PRE
1
2
3
4
6
8
12
24
48
72
Hours
24 hr % of Baseline
135±32
37 ± 4.7
24 ± 4.4
23 ± 8.3
1.6 ± 0.98
1.9 ± 0.41
Placebo (n=8)
50 mg (n=6)
150 mg (n=6)
300 mg (n=6)
600 mg (n=6)
1000 mg (n=6)

Figure 22.



% Change in Urinary LTE4 Levels
(Single Dose Cohort)
Urinary LTE4
(% Baseline)
Hours
Placebo (n=10)
50 mg
150 mg
300 mg
600 mg
1000 mg
210
190
170
150
130
110
100
90
80
70
60
50
40
30
20
10
0
0 3 6 9 12 16 24 36 48 72

Figure 23.



Plasma Concentrations of Compound Following Multiple Dose Administration
Plasma Conc (ng/mL)
2000
1500
1000
500
0
0
24
48
72
96
120
144
168
192
216
240
264
288
312
Time (hr)

Figure 24.



Cohort 6 - 150 mg
% Change in LTB4 levels
(Multiple Dose Cohort)
% Baseline
225
200
175
150
125
100
75
50
25
0
PRE 2 4 6 8 12 24
0 2 4 6 8 12 24 48 72
Day 1
Day 11
P1
P2
P3
P4
P5
P6
P7
P8

Figure 25.